Johnson & Johnson $JNJ Position Increased by Diversify Wealth Management LLC

Diversify Wealth Management LLC grew its position in Johnson & Johnson (NYSE:JNJ) by 239.4% in the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 90,061 shares of the company’s stock after purchasing an additional 63,524 shares during the period. Diversify Wealth Management LLC’s holdings in Johnson & Johnson were worth $20,475,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Pittenger & Anderson Inc. lifted its position in shares of Johnson & Johnson by 1.4% in the 1st quarter. Pittenger & Anderson Inc. now owns 96,991 shares of the company’s stock valued at $23,709,000 after acquiring an additional 1,303 shares in the last quarter. Kaizen Financial Strategies acquired a new position in Johnson & Johnson in the 1st quarter worth approximately $213,000. Ferguson Wellman Capital Management Inc. grew its position in Johnson & Johnson by 75.3% during the 1st quarter. Ferguson Wellman Capital Management Inc. now owns 469,028 shares of the company’s stock worth $114,649,000 after purchasing an additional 201,519 shares in the last quarter. Capital Squared Financial LLC acquired a new stake in Johnson & Johnson during the 1st quarter valued at $212,000. Finally, Citizens Financial Group Inc. RI raised its stake in Johnson & Johnson by 4.0% during the 1st quarter. Citizens Financial Group Inc. RI now owns 206,800 shares of the company’s stock valued at $50,550,000 after purchasing an additional 7,966 shares during the period. Institutional investors and hedge funds own 69.55% of the company’s stock.

More Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Analysts expect Johnson & Johnson to post a solid Q2 print, with commentary pointing to an upbeat report even as Stelara faces headwinds. Johnson & Johnson: Analysts see upbeat Q2 print despite Stelara headwinds
• Positive Sentiment: Several preview pieces say JNJ is trading near all-time highs and could still have more upside if earnings and guidance come in strong. Johnson & Johnson Q2 Preview: Stock Near All-Time Highs, Market Expert Sees Rally to $282
• Positive Sentiment: RBC raised its price target on JNJ to $287 from $265 and maintained an outperform rating, reinforcing bullish sentiment.
• Positive Sentiment: Coverage also highlighted JNJ’s strong year-to-date run and defensive healthcare appeal, which has supported investor demand ahead of earnings. Johnson & Johnson Reports Q2 Earnings Tomorrow. What Investors Should Expect.
• Neutral Sentiment: Other articles focused on JNJ as a dividend and income stock, which may support valuation but did not add new material catalysts. How to earn $500 a month from Johnson & Johnson stock ahead of Q2 earnings
• Negative Sentiment: Some commentary noted the stock’s rich valuation after a big rally, suggesting investors may be paying a premium heading into the report. What Lilly’s Peer-Beating Numbers Cost You

Insiders Place Their Bets

In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 10,000 shares of the company’s stock in a transaction dated Thursday, June 11th. The stock was sold at an average price of $241.15, for a total value of $2,411,500.00. Following the transaction, the executive vice president directly owned 114,288 shares of the company’s stock, valued at $27,560,551.20. This represents a 8.05% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.16% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several brokerages have recently commented on JNJ. JPMorgan Chase & Co. raised their target price on Johnson & Johnson from $250.00 to $260.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 15th. Morgan Stanley upped their price target on Johnson & Johnson from $283.00 to $284.00 and gave the company an “overweight” rating in a research report on Wednesday, July 8th. Guggenheim increased their price objective on Johnson & Johnson from $266.00 to $270.00 and gave the stock a “buy” rating in a research note on Friday, June 26th. Leerink Partners raised Johnson & Johnson from a “market perform” rating to an “outperform” rating and set a $265.00 target price on the stock in a research note on Wednesday, May 13th. Finally, Citigroup upped their target price on Johnson & Johnson from $285.00 to $298.00 and gave the company a “buy” rating in a report on Wednesday, July 8th. Twenty investment analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $261.26.

Johnson & Johnson Trading Down 1.6%

Johnson & Johnson stock opened at $253.70 on Wednesday. Johnson & Johnson has a 12 month low of $154.80 and a 12 month high of $269.43. The company has a quick ratio of 0.77, a current ratio of 1.03 and a debt-to-equity ratio of 0.46. The stock has a market cap of $610.71 billion, a P/E ratio of 29.33, a P/E/G ratio of 2.46 and a beta of 0.24. The company’s fifty day simple moving average is $238.18 and its 200-day simple moving average is $233.92.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, April 14th. The company reported $2.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.68 by $0.02. The business had revenue of $24.06 billion during the quarter, compared to analyst estimates of $23.60 billion. Johnson & Johnson had a return on equity of 32.60% and a net margin of 21.83%.Johnson & Johnson’s quarterly revenue was up 9.9% compared to the same quarter last year. During the same period last year, the company earned $2.77 earnings per share. As a group, sell-side analysts forecast that Johnson & Johnson will post 11.58 EPS for the current fiscal year.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.